Novel combinations for the treatment of metastatic breast cancer

Anthracyclines and taxanes represent the mainstay of first-line cytotoxic therapy for metastatic breast cancer (MBC), but most patients eventually develop resistance to these agents. Consequently, alternative combinations for MBC therapy are the subject of much ongoing research. Capecitabine and ixa...

Descripción completa

Detalles Bibliográficos
Autor principal: Vahdat, Linda T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827587/
https://www.ncbi.nlm.nih.gov/pubmed/24281029
http://dx.doi.org/10.3390/cancers2010001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827587/
https://www.ncbi.nlm.nih.gov/pubmed/24281029
http://dx.doi.org/10.3390/cancers2010001

Ejemplares similares